The oncogenic mechanism in neuroblastoma operates by activation of RAS-MAPK-ERK and other downstream pathways, and can be initiated by activating mutations of ALK, ALK amplifications, or, possibly, changes to the ALK ligands ALKAL1 and ALKAL2 [82–84]. Here, ALK is linked to neuroblastoma.